SureNano Science’s Subsidiary GlucaPharm Targets Obesity and Diabetes with Novel Triple Agonist Peptide GEP-44

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial spotlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions.

The GLP-1 drug class has seen explosive growth, driven by blockbuster medications like semaglutide and tirzepatide, which have demonstrated significant weight loss and glycemic control. However, tolerability issues and the need for injectable delivery remain barriers for many patients. GlucaPharm’s GEP-44 aims to address these limitations by targeting three key receptors simultaneously—GLP-1, GIP, and glucagon—potentially offering improved efficacy and a more favorable side effect profile. Additionally, the peptide may be suitable for non-injectable delivery, which could expand patient access and convenience.

SureNano Science acquired GlucaPharm as part of its strategic pivot toward pharmaceutical innovation. The company notes that GEP-44 is protected by patents and is in preclinical development. The press release states that the initial business of SureNano Science remains the sale and distribution of the SureNano surfactant, a food-grade compound for nanoemulsions, but the company is now developing into a pharmaceutical-focused entity through the advancement of this therapeutic candidate.

The editorial coverage from BioMedWire, a brand within the IBN network, underscores the growing interest in next-generation metabolic therapies. IBN’s InvestorWire platform distributes press releases and editorial content to a wide audience of investors and industry professionals. The full press release is available at https://ibn.fm/rq75B.

Obesity and type 2 diabetes represent a massive global health challenge, with millions affected worldwide. The demand for more effective and tolerable treatments continues to drive research into novel peptides and delivery methods. If GEP-44 succeeds in clinical development, it could offer a differentiated option in a crowded market, potentially improving patient outcomes and adherence. The triple agonist approach, similar to that used in tirzepatide but with the addition of glucagon agonism, may provide enhanced weight loss and metabolic benefits.

SureNano Science is based in Canada and is listed on the Canadian Securities Exchange and OTCQB. The company’s newsroom provides updates on its progress (https://ibn.fm/SURNF). However, as with all early-stage biotech ventures, risks remain regarding regulatory approval, clinical trial outcomes, and commercialization.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is SureNano Science’s Subsidiary GlucaPharm Targets Obesity and Diabetes with Novel Triple Agonist Peptide GEP-44.

The post SureNano Science’s Subsidiary GlucaPharm Targets Obesity and Diabetes with Novel Triple Agonist Peptide GEP-44 appeared first on citybuzz.